Drug Repositioning for Neurodegenerative Diseases

📖 Wiki Page

therapeutic1372 wordssynced 2026-04-02

Drug Repositioning for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Drug Repositioning for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Original Use</td>
</tr>
<tr>
<td class="label">Ambroxol</td>
<td>Mucolytic</td>
</tr>
<tr>
<td class="label">Memantine</td>
<td>Dementia</td>
</tr>
<tr>
<td class="label">Valproic Acid</td>
<td>Epilepsy/BD</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Bipolar</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>Hypertension</td>
</tr>
<tr>
<td class="label">Nimodipine</td>
<td>Stroke</td>
</tr>
<tr>
<td class="label">Zonisamide</td>
<td>Epilepsy</td>
</tr>
</table>

Drug Repositioning For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

...

Drug Repositioning for Neurodegenerative Diseases

Introduction

Overview

Mermaid diagram (expand to render)

Drug repositioning (also known as drug repurposing) is a strategic approach to identifying new therapeutic applications for existing drugs that were originally developed for different conditions. This overview explains the drug repositioning methodology, its advantages over traditional drug development, and its growing importance in neurodegenerative disease therapy development.

In the context of neurodegenerative diseases, drug repositioning offers a faster and more cost-effective path to clinical translation compared to developing novel compounds from scratch. Many drugs with established safety profiles are being investigated for neuroprotective effects in Alzheimer's disease, Parkinson's disease, ALS, and other conditions.

Overview

Drug repositioning (also called drug repurposing) is a strategic approach to identify existing FDA-approved drugs for new therapeutic applications in neurodegenerative diseases. This approach leverages known safety profiles, pharmacokinetics, and manufacturing processes to accelerate the development timeline and reduce costs compared to de novo drug development[@pushpakom2019].

The high failure rate and enormous costs associated with developing new drugs for neurodegenerative diseases have made repositioning an attractive strategy. By identifying existing drugs that may have disease-modifying effects in conditions like Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease, researchers can potentially bring new treatments to patients faster than traditional drug development pathways allow.

Rationale for Repositioning

Advantages Over De Novo Development

Reduced development time: 3-12 years vs. 10-15 years for new drugs
Lower development costs: Estimated $1-2 billion vs. $2-6 billion
Established safety profiles: Extensive clinical safety data available
Known pharmacokinetics: ADME properties already characterized
Regulatory pathway: May qualify for 505(b)(2) approval pathway[@ashburn2004]

Challenges

Patent considerations: May require new formulation or dosing patents
Intellectual property: Original compound patents may limit exclusivity
Mechanistic uncertainty: Understanding of new indications may be incomplete
Dosing optimization: May require different dosing for new indications[@sleire2017]